Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
NONO
NoNO is a clinical-stage biotherapeutics company that develops pharmaceuticals for common health disorders.
Sector
Subsector
Location
total rounds
total raised
ATXA Therapeutics
ATXA is a clinical-stage pharmaceutical company that develops novel small molecule drugs to treat Pulmonary Arterial Hypertension.
Sector
Subsector
Keywords
Location
total rounds
total raised
Tonix Pharmaceuticals Holding
Tonix Pharmaceuticals is developing innovative therapies and vaccines to improve population health.
Sector
Subsector
Keywords
Location
total rounds
total raised
Marinus Pharmaceuticals
Marinus Pharmaceuticals develops and commercializes ganaxolone for neurological and psychiatric disorders.
Sector
Subsector
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Mast Therapeutics
announced date
price
Financials
Funding Rounds1
Number of Funding Rounds
Money Raised
Their latest funding was raised on 11.11.2010. Their latest investor ProQuest Investments. Their latest round Series B
ProQuest Investments
ProQuest Investments is a healthcare venture capital firm seeking to finance seed- to late-stage healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
MPM Capital
MPM Capital invests in early-stage healthcare companies developing innovative oncology technologies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Co-Investors
Investors2
Number of lead investors
Number of investors
ProQuest Investments
ProQuest Investments is a healthcare venture capital firm seeking to finance seed- to late-stage healthcare companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
MPM Capital
MPM Capital invests in early-stage healthcare companies developing innovative oncology technologies.
Sector
Subsector
Location
count Of Investments
count Of Exists
William Greene
William Greene, M.D., joined MPM in 2002 and has led investments in biopharmaceuticals, medical devices and pharma services. Bill is currently serving as CEO of MPM portfolio company Iconic Therapeutics, Inc., which is developing novel therapeutics for ophthalmologic diseases and cancer. He currently also sits on the Board of Sai Advantium Pharma. Bill’s Board and investment experience includes Alnara (acquired by Eli Lilly:LLY), Alsius (Acquired, Zoll), Barrier Therapeutics (BTRX), Cotherix (CTRX), Idun Pharmaceuticals (acquired by Pfizer:PFE), and Intercell AG (ICLL, Vienna Stock Exchange). In addition to investing and serving on corporate boards, Bill has filled roles with portfolio companies including interim VP of Regulatory Affairs, Chief Medical Officer and Scientific and Clinical Development Advisory Boards. Prior to joining MPM, Bill was at Genentech (acquired by Roche:RHHBY) where he served as a Senior Clinical Scientist and Epidemiologist with responsibilities in clinical strategy, trial design and regulatory affairs in several therapeutic areas at all phases of drug development from translational research through post-marketing studies. His experience there included leading the clinical development of Lucentis® from IND through Phase II. Prior to Genentech, Bill was at Yale Medical School where he studied, taught, and performed clinical research in Internal Medicine and Diagnostic Radiology. He was an Assistant Clinical Professor of Medicine at UCSF from 1998-2005, active on the teaching staff of San Francisco General Hospital. Bill received a B.A. degree from Wesleyan University and an M.D. degree from UCSF. He has been a Robert Wood Johnson Clinical Scholar at Yale (clinical epidemiology) and a Howard Hughes Medical Institute Research Scholar at the NIH (neurobiology). In addition to his work with MPM, Bill’s passion for using biotechnology to address significant unmet human needs extends to global health. He is an advisor to the Bill and Melinda Gates Foundation and is Chairman of the Board of the Global Health Investment Fund, a pioneering initiative supported by the Foundation that brings together investors, philanthropists and industry to forge creative solutions to bring the fruits of biotechnology to the underserved around the world.
current job
People
Employee Profiles4
Julie Crawford
Sr. Director of Finance and Administration